Foulds G, Stankewich J P, Marshall D C, O'Brien M M, Hayes S L, Weidler D J, McMahon F G
Antimicrob Agents Chemother. 1983 May;23(5):692-9. doi: 10.1128/AAC.23.5.692.
Sulbactam, a new beta-lactamase inhibitor, has pharmacokinetic characteristics in humans similar to those of ampicillin and amoxicillin. Its half-life in humans is approximately 1 h. In a two-compartment pharmacokinetic model, the apparent volume of distribution for the central compartment is approximately 12 liters, and half of the dose is found in the central compartment in the postdistributive phase. Approximately 75% of a parenteral dose is excreted unchanged in urine. The coadministration of sulbactam with ampicillin, penicillin G, or cefoperazone has essentially no effect upon the kinetics of either the beta-lactam antibiotic or sulbactam.
舒巴坦是一种新型β-内酰胺酶抑制剂，其在人体内的药代动力学特征与氨苄西林和阿莫西林相似。它在人体内的半衰期约为1小时。在二室药代动力学模型中，中央室的表观分布容积约为12升，在分布后阶段，一半的剂量存在于中央室。静脉注射剂量的约75%以原形经尿液排泄。舒巴坦与氨苄西林、青霉素G或头孢哌酮合用对β-内酰胺类抗生素或舒巴坦的动力学基本没有影响。
